SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec - Quaterly Results

30 May 2024 Evaluate
The company witnessed a 7.13% growth in the revenue at Rs. 803.70 millions for the quarter ended March 2024 as compared to Rs. 750.20 millions during the year-ago period.The Net Loss for the quarter ended March 2024 is Rs. -13.70 millions as compared to Net Loss of Rs. -196.90 millions of corresponding quarter ended March 2023Operating Profit reported a sharp decline to 71.50 millions from 137.00 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 803.70 750.20 7.13 3596.00 2570.70 39.88 3596.00 2570.70 39.88
Other Income 163.90 102.70 59.59 249.10 344.30 -27.65 249.10 344.30 -27.65
PBIDT 71.50 137.00 -47.81 390.80 -281.90 -238.63 390.80 -281.90 -238.63
Interest 33.60 27.00 24.44 137.80 100.60 36.98 137.80 100.60 36.98
PBDT 37.90 110.00 -65.55 253.00 -382.50 -166.14 253.00 -382.50 -166.14
Depreciation 51.40 59.00 -12.88 210.90 245.00 -13.92 210.90 245.00 -13.92
PBT -13.50 51.00 -126.47 42.10 -627.50 -106.71 42.10 -627.50 -106.71
TAX 0.20 247.90 -99.92 6.60 247.90 -97.34 6.60 247.90 -97.34
Deferred Tax 0.20 247.90 -99.92 0.20 247.90 -99.92 0.20 247.90 -99.92
PAT -13.70 -196.90 -93.04 35.50 -875.40 -104.06 35.50 -875.40 -104.06
Equity 61.30 61.30 0.00 61.30 61.30 0.00 61.30 61.30 0.00
PBIDTM(%) 8.90 18.26 -51.28 10.87 -10.97 -199.10 10.87 -10.97 -199.10

Panacea Biotec Share Price

358.00 5.30 (1.50%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×